Clinical Trials for Ovarian Cancer

MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (any platinum sensitivity; measurable and/or CA-125–evaluable disease; no prior PD‑1/PD‑L1) receive an autologous folate receptor alpha–loaded dendritic cell vaccine plus pembrolizumab. The FRαDC vaccine (monocyte-derived DCs pulsed with multi-epitope FRα peptides to enhance antigen presentation and T‑cell priming against FRα‑overexpressing tumors) is given intradermally alongside standard anti–PD‑1 therapy on a defined 21–42‑day schedule to assess safety and objective response.

ClinicalTrials.gov ID: NCT05920798

Randomized Phase I Study Assessing the Safety and Tolerability Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Completion of Interval Cytoreductive Surgery Compared to Surgery and Chemotherapy Prior to Surgery for Patients With Stage III/IV Ovarian Cancer Undergoing Neoadjuvant Chemotherapy.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with newly diagnosed stage III–IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who responded to 3–4 cycles of neoadjuvant carboplatin/paclitaxel and are candidates for interval cytoreductive surgery are randomized to perioperative cisplatin either IV the day before surgery or as intraoperative HIPEC at the end of surgery. Compares safety/tolerability and feasibility of these cisplatin delivery strategies in the perioperative setting.

ClinicalTrials.gov ID: NCT05415709

Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent low-grade serous ovarian cancer (measurable disease, ECOG 0–2; up to 5 prior lines; no prior regorafenib or multi-kinase TKIs; limited prior anti-angiogenic therapy) receive regorafenib (oral multikinase inhibitor of VEGFR/PDGFR/FGFR/RAF; ReDOS ramp-up, 3 weeks on/1 week off) plus intramuscular fulvestrant 500 mg (SERD). Aims to assess early objective response and survival/clinical benefit, with safety monitoring and exploratory genomic correlates.

ClinicalTrials.gov ID: NCT05113368

A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent mismatch repair–deficient endometrial carcinoma (non-serous, non-carcinosarcoma) after 1–2 prior lines are randomized to nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) versus nivolumab alone, including patients with treated/stable brain metastases and select stable autoimmune disease; prior PD-1/PD-L1 allowed only if part of combination therapy with ≥12-month CR interval. Treatment continues until progression/toxicity/CR with nivolumab maintenance permitted after CR.

ClinicalTrials.gov ID: NCT05112601

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves patients with advanced or metastatic solid tumors expressing Nectin-4, including urothelial carcinoma, triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer, who have exhausted standard therapy options. It evaluates LY4052031, an antibody-drug conjugate that targets Nectin-4 to deliver a topoisomerase I inhibitor, aiming to assess its safety, tolerability, and efficacy in these patients.

ClinicalTrials.gov ID: NCT06465069

A First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: The trial involves patients with platinum-resistant high-grade ovarian cancer or relapsed/refractory non-small cell lung cancer, assessing the safety and efficacy of TUB-040, an antibody-drug conjugate targeting NaPi2b with a topoisomerase I inhibitor, administered every three weeks.

ClinicalTrials.gov ID: NCT06303505

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial investigates LNCB74, a B7-H4 targeted antibody-drug conjugate, as monotherapy for adults with advanced, unresectable, or metastatic solid tumors that express B7-H4, aiming to evaluate its safety, tolerability, and efficacy. Participants must have measurable disease, an ECOG performance status of 0-1, and adequate organ function.

ClinicalTrials.gov ID: NCT06774963

A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with unresectable or metastatic solid tumors (including NSCLC, high-grade serous ovarian carcinoma, and uterine serous carcinoma), ECOG 0-1, and at least one accessible lesion for biopsy. Patients receive BMS-986463, a novel investigational antineoplastic agent with an undisclosed mechanism of action, as monotherapy.

ClinicalTrials.gov ID: NCT06476808

An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced, recurrent, or metastatic solid tumors (including platinum-resistant ovarian cancer, triple-negative breast cancer, squamous cell carcinoma of the anus or head and neck, non-small cell lung cancer, and uterine serous cancer) who have progressed on all standard therapies, to receive SMP-3124LP, a novel liposomal CHK1 inhibitor given by intravenous infusion. SMP-3124LP targets the DNA damage response pathway and is being assessed for safety, tolerability, and preliminary efficacy.

ClinicalTrials.gov ID: NCT06526819

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with recurrent, unresectable, locally advanced, or metastatic solid tumors—including colorectal, pancreatic, NSCLC, ovarian cancer, mesothelioma, and others—that express mesothelin (MSLN) and have lost HLA-A*02 expression, who are heterozygous for HLA-A*02. Eligible patients receive a single infusion of A2B694, an autologous CAR T-cell therapy engineered with a logic-gated Tmod system to selectively target MSLN-positive, HLA-A*02-negative tumor cells.

ClinicalTrials.gov ID: NCT06051695